10374 Federal Register / Vol. 76, No. 37 / Thursday, February 24, 2011 / Notices 

Over 3 years 

William F. Ryan ............. 2,400 

Total ............................... 18,980 

E-mail comments to 

paperwork@hrsa.gov or mail the HRSA 

Reports Clearance Officer, Room 10–33, 

Parklawn Building, 5600 Fishers Lane, 

Rockville, MD 20857. Written comments 

should be received within 60 days of 

this notice. 

Dated: February 17, 2011. 

Reva Harris, 

Acting Director, Division of Policy and 

Information Coordination. 

[FR Doc. 2011–4162 Filed 2–23–11; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

Federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

LightCensor: A Detecting and Control 

Program That Guarantees That a 

Mobile Device Be Used Only in 

Appropriate Lighting Conditions When 

Displaying Medical Images 

Description of Invention: The 

invention provides algorithm that when 

used in a mobile device (e.g. 

smartphone) can enhance the 

capabilities of mobile devices to be used 

by medical professionals for medical 

imaging. 

Thanks to its swiftly improved 

display quality, the smartphone has 

been advocated by the medical imaging 

vendors for viewing medical images in 

specific conditions that require urgency 

of the read or when full-size workstation 

displays are not readily available. 

However, as a hand-held device, the 

viewing conditions of a smartphone (e.g. 

ambient light and hand shaking) are not 

predictable and may adversely affect the 

perceived image quality. The present 

invention proposes the use of the builtin sensors in iPhone-like mobile devices 

to detect and adapt to the viewing 

conditions and hand shaking. The builtin camera can be used to capture the 

ambient light for determining the 

adaptation level, which affects the 

brightness, contrast and color 

perception. The built-in accelerometers 

can be used to detect orientation and 

moving velocity of the display, which 

affect the perceived spatial resolution. 

The execution of critical tasks can be 

then censored based on the detected 

scenario. If the viewing conditions are 

not suitable for reading medical images, 

for example, then the program could 

halt until the viewing conditions 

improve. 

This invention can be used by 

consumer-grade mobile devices which 

were not originally designed for medical 

purposes to show medical images with 

improved perceived image quality. 

Applications 

• Biomedical imaging. 

• Radiology. 

Advantages: Improved image quality 

of mobile devices that minimizes issues 

related to inadequate light conditions or 

hand movement. 

Development Status 

• Algorithm developed. 

• Prototype is being built. 

Inventors: Wei-Chung Cheng and 

Aldo G. Badano (FDA). 

Patent Status: HHS Reference No. E– 

284–2010/0—Research Tool/Software. 

Patent protection is not being pursued 

for this technology. 

Licensing Status: Available for 

licensing. 

Licensing Contacts 

• Uri Reichman, PhD, MBA; 301– 

435–4616; UR7a@nih.gov. 

• Michael Shmilovich, Esq.; 301– 

435–5019; ShmilovichM@mail.nih.gov. 

A Novel MRI Phantom for Breast 

Imaging 

Description of Invention: The 

invention offered for licensing is in the 

field of breast cancer imaging. More 

specifically it relates to novel breast 

phantoms that can be used as reference 

in breast imaging. The anthropomorphic 

breast phantoms described in the 

invention comprise a combination of 

adipose tissue mimicking components 

and fibroglandular tissue mimicking 

components. Typically, x-ray 

attenuation coefficients or magnetic 

resonance relaxation times T1 and T2 

are selected that are sufficiently similar 

to actual patient tissues. The mimicking 

components are distributed within the 

phantom such that images of the 

phantom contain features similar to 

those of patient tissues. A breast 

phantom can be based on a lard/egg 

white combination that is shaped to 

approximate a human breast, or a 

compressed human breast as prepared 

for mammography. The phantoms can 

include lesion chambers that permit the 

introduction of contrast agents to 

simulate benign or malignant lesions, 

and contrast agent concentration can be 

time varied to produce washout curves. 

Applications: Imaging of breast cancer 

as well as calibration and optimization 

of related instrumentation. 

Advantages: The breast phantoms of 

the invention precisely mimics human 

breast in several of their characteristics 

as mentioned above. Furthermore, they 

can be utilized in conjunction with xray mammography and/or with MRI. 

The phantoms may therefore be used to 

enhance the accuracy and quality of 

diagnostic breast imaging, and thus 

avoid unnecessary procedures. In 

addition, wide-spread use of the breast 

phantoms will lead to improved 

standardization in the field of breast 

imaging. 

Development Status: The methods of 

making the phantoms have been 

established. Clinical usefulness has to 

be established. 

Inventors: Melanie Freed and Aldo 

Badano (FDA). 

Patent Status 

• U.S. Provisional Application No. 

61/385,929 filed 23 Sep 2010 (HHS 

Reference No. E–126–2010/0–US–01), 

entitled ‘‘Evaluation of Breast Dynamic 

Contrast-enhanced Magnetic Resonance 

Imaging’’. 

• U.S. Provisional Application No. 

61/424,495 filed 17 Dec 2010 (HHS 

Reference No. E–126–2010/1–US–01), 

entitled ‘‘Anthropomorphic, X-ray and 

Dynamic Contrast-Enhanced Magnetic 

Resonance Imaging Phantom for 

Quantitative Evaluation of Breast 

Imaging Techniques’’. 

Licensing Status: Available for 

licensing. 


emcdonald on DSK2BSOYB1PROD with NOTICES
Federal Register / Vol. 76, No. 37 / Thursday, February 24, 2011 / Notices 10375 

Licensing Contacts 

• Uri Reichman, PhD, MBA; 301– 

435–4616; UR7a@nih.gov. 

• John Stansberry, PhD; 301–435– 

5236; Stansbej@mail.nih.gov. 

Meningococcal and Pneumococcal 

Conjugate Vaccine and Method of Using 

Same 

Description of Invention: 

Pneumococcal diseases are a major 

public health problem all over the 

world. The etiological agent, 

Streptococcus pneumoniae (the 

pneumococcus) is surrounded by a 

polysaccharide capsule. Differences in 

the composition of this capsule permit 

serological differentiation between 

about 90 capsular types, some of which 

are frequently associated with 

pneumococcal disease, others rarely. 

Invasive pneumococcal infections 

include pneumonia, meningitis and 

febrile bacteremia; among the common 

non-invasive manifestations are otitis 

media, sinusitis and bronchitis. At least 

1 million children die of pneumococcal 

disease every year, most of these being 

young children in developing countries. 

Vaccination is the only available tool to 

prevent pneumococcal disease. The 

recent development of widespread 

microbial resistance to essential 

antibiotics underlines the urgent need 

for more efficient pneumococcal 

vaccines. 

Meningococcal disease is a contagious 

bacterial disease caused by the 

meningococcus (Neisseria meningitidis). 

It is spread by person-to-person contact 

through respiratory droplets of infected 

people. There are 3 main clinical forms 

of the disease: the meningeal syndrome, 

the septic form and pneumonia. The 

onset of symptoms is sudden and death 

can follow within hours. In as many as 

10–15% of survivors, there are 

persistent neurological defects, 

including hearing loss, speech 

disorders, loss of limbs, mental 

retardation and paralysis. Up to 5–10% 

of a population may be asymptomatic 

carriers. These carriers are crucial to the 

spread of the disease as most cases are 

acquired through exposure to 

asymptomatic carriers. Waning 

immunity among the population against 

a particular strain favors epidemics, as 

do overcrowding and climatic 

conditions such as dry seasons or 

prolonged drought and dust storms. The 

disease mainly affects young children, 

but is also common in older children 

and young adults. The disease occurs 

sporadically throughout the world with 

seasonal variations and accounts for a 

proportion of endemic bacterial 

meningitis. However, the highest 

burden of the disease is due to the 

cyclic epidemics occurring in the 

African meningitis belt. 

With the burden of S. pneumoniae 

and N. meningitidis infection on the 

public health system at a global scale, it 

is desirable to have a single vaccine that 

is effective to prevent disease resulting 

from the infection of both pathogens. 

This application claims immunogenic 

compositions for inducing an immune 

response to two different 

microorganisms, S. pneumoniae and N. 

meningitidis. The application also 

claims conjugate vaccines comprising at 

least one N. meningitidis capsular 

polysaccharide conjugated to a 

recombinant pneumococcal protein. 

Applications: Conjugate vaccine for 

the prevention and/or therapy of 

meningococcal and pneumococcal 

infections. 

Advantages 

• Rapid production time. 

• Higher-yielding manufacturing 

method. 

• Low manufacturing cost. 

Development Status: Preclinical 

studies have been conducted by the 

inventors. 

Inventors 

• Stanley S. Tai (Howard University). 

• Che-Hung Robert Lee (FDA). 

Patent Status: HHS Reference No. E– 

030–2010/0— 

• U.S. Patent Application No. 12/ 

425,232 filed 16 Apr 2009. 

• PCT/US2010/031083 filed 14 Apr 

2010. 

Licensing Status: Available for 

licensing. 

Licensing Contact: Daniel G. McCabe; 

Associate General Counsel for Business 

Transactions; Howard University, Office 

of the General Counsel; 2400 6th Street, 

NW., Suite 321; Washington, DC 20059; 

Office: (202) 806–2650; Fax: (202) 806– 

6357; E-mail: dmccabe@howard.edu. 

Dated: February 16, 2011. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2011–4171 Filed 2–23–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Terahertz Spatial Light Modulator 

System for Adaptive Near-Field 

Imaging 

Description of Technology: The 

invention offered for licensing is in the 

field of imaging microscopes and relates 

to a terahertz light modulator system, 

and in particular to a terahertz spatial 

light modulator system for adaptive 

near-field imaging. 

More specifically, the invention 

relates to a spatial light modulator 

system for adaptive near-field imaging 

having an optical source for transmitting 

an optical beam through a filter which 

is controlled to convert the optical light 

beam into a filtered optical light beam 

to define one or more transmission 

pathways through a photoconductive 

material. The system further includes a 

terahertz light source for transmitting a 

terahertz beam through one or more 

transmission pathways defined by the 

filtered optical light beam through the 

photoconductive material for 

illuminating and scanning the sample 

without the use of moving structural 

components. The device would allow 

micron-scale spatial resolution, would 

remove the need to mechanically scan a 

sample, and would allow automatic 

adjustment of image resolution and 

transmitted terahertz power. The nearfield terahertz microscope of the 

invention could have a compact, fibercoupled sensor head with no moving 

parts—ideal for scientific, medical, and 

industrial applications like crystal 

growth optimization, skin cancer 

diagnosis, and semiconductor chip 

inspection. In one application, such as 

‘‘one-cut’’ surgery, the compact sensor 


emcdonald on DSK2BSOYB1PROD with NOTICES